{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Day+78+Assessments", "query": { "intervention": "Day 78 Assessments" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T07:49:37.931Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01585350", "title": "A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)", "type": "BIOLOGICAL" }, { "name": "MELITAC 12.1 + Montanide ISA-51 + polyICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2012-10", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2016-08-12", "last_synced_at": "2026-09-04T07:49:37.931Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585350" }, { "nct_id": "NCT04722887", "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alpha1-Antitrypsin Deficiency" ], "interventions": [ { "name": "Alpha-1 15%", "type": "BIOLOGICAL" }, { "name": "Liquid Alpha1-Proteinase Inhibitor (Human)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 17, "start_date": "2021-08-13", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-09-04T07:49:37.931Z", "location_count": 5, "location_summary": "Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04722887" }, { "nct_id": "NCT01846143", "title": "Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "pBCAR3-phosphopeptide", "type": "BIOLOGICAL" }, { "name": "pIRS2-phosphopeptide", "type": "BIOLOGICAL" }, { "name": "2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2013-05", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2016-08-12", "last_synced_at": "2026-09-04T07:49:37.931Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01846143" }, { "nct_id": "NCT01190930", "title": "Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Adult B Lymphoblastic Lymphoma", "Ann Arbor Stage I B Lymphoblastic Lymphoma", "Ann Arbor Stage II B Lymphoblastic Lymphoma", "Childhood B Acute Lymphoblastic Leukemia", "Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Childhood B Lymphoblastic Lymphoma", "Down Syndrome", "Hypodiploid B Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 9350, "start_date": "2010-08-11", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-09-04T07:49:37.931Z", "location_count": 213, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01190930" }, { "nct_id": "NCT01264731", "title": "Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "MELITAC 12.1", "type": "BIOLOGICAL" }, { "name": "Imiquimod", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2011-01", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-09-04T07:49:37.931Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01264731" }, { "nct_id": "NCT00449150", "title": "Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Benign Prostatic Hypertrophy" ], "interventions": [ { "name": "Cetrorelix 78 mg + 78 mg", "type": "DRUG" }, { "name": "Cetrorelix 78 mg + 52 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AEterna Zentaris", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "MALE", "summary": "50 Years and older · Male only" }, "enrollment_count": 667, "start_date": "2007-03", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2018-08-03", "last_synced_at": "2026-09-04T07:49:37.931Z", "location_count": 46, "location_summary": "Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00449150" }, { "nct_id": "NCT05972265", "title": "Childhood Trauma, Exercise, and Cognition", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adverse Childhood Experiences" ], "interventions": [ { "name": "Moderate Intensity Exercise (one day)", "type": "BEHAVIORAL" }, { "name": "Placebo - Light Intensity Exercise (one day)", "type": "BEHAVIORAL" }, { "name": "Moderate Intensity Exercise (9 wks)", "type": "BEHAVIORAL" }, { "name": "Day 1 Assessments", "type": "OTHER" }, { "name": "Symptom Measures and Neuropsychological Tests", "type": "OTHER" }, { "name": "Day 36 Assessments", "type": "OTHER" }, { "name": "Day 57 Assessments", "type": "OTHER" }, { "name": "Day 78 Assessments", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "University of Texas at Austin", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "40 Years to 60 Years" }, "enrollment_count": 34, "start_date": "2023-11-27", "completion_date": "2027-06-04", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-04T07:49:37.931Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05972265" }, { "nct_id": "NCT03617328", "title": "Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "6MHP", "type": "BIOLOGICAL" }, { "name": "Montanide ISA-51", "type": "DRUG" }, { "name": "polyICLC", "type": "DRUG" }, { "name": "CDX-1127", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2018-11-13", "completion_date": "2024-01-19", "has_results": false, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-09-04T07:49:37.931Z", "location_count": 2, "location_summary": "Charlottesville, Virginia • Richmond, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03617328" } ] }